It is known that patients with advanced BC have undergone prior aromatase inhibitor therapy followed by a selection of ESR1 mutations by the time of tumor progression; therefore, attempts are being made to find new effective combinations for their treatment. This evidence concerns the gene CYP19A1 and neoplasm.